Trials / Recruiting
RecruitingNCT07083011
A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure
A Three-Arm, Observational, Pilot Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the performance of 68Ga- FAPI PET in heart failure with preserved ejection fraction (HFpEF)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor) | 68Ga-FAPI is a gallium-68 fibroblast activation protein inhibitor that will be injected into subjects during a PET (positron emission tomography) scan |
Timeline
- Start date
- 2025-11-01
- Primary completion
- 2027-07-01
- Completion
- 2027-07-01
- First posted
- 2025-07-24
- Last updated
- 2025-09-25
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07083011. Inclusion in this directory is not an endorsement.